Aligos Therapeutics (NASDAQ:ALGS) Receives Sell (D-) Rating from Weiss Ratings

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities researchers at Weiss Ratings in a research report issued to clients and investors on Friday,Weiss Ratings reports.Separately, HC Wainwright reissued a "buy" rating and set a $50.00 price target on shares of Aligos Therapeutics in a research report on Friday, September 12th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $50.00.Get Aligos Therapeutics alerts:Check Out Our Latest Report on ALGSAligos Therapeutics Stock PerformanceALGS traded up $0.20 on Friday, hitting $9.69. 26,275 shares of the company were exchanged, compared to its average volume of 150,831. Aligos Therapeutics has a 12 month low of $3.76 and a 12 month high of $46.80. The company has a market cap of $59.59 million, a PE ratio of -0.49 and a beta of 2.77. The stock's fifty day moving average is $10.07 and its 200-day moving average is $7.87. Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.53) earnings per share for the quarter, topping analysts' consensus estimates of ($2.35) by $0.82. The firm had revenue of $0.97 million for the quarter, compared to the consensus estimate of $0.43 million. Aligos Therapeutics had a negative return on equity of 22.41% and a negative net margin of 2,337.24%. As a group, equities research analysts expect that Aligos Therapeutics will post -10.36 EPS for the current fiscal year. Hedge Funds Weigh In On Aligos TherapeuticsSeveral institutional investors and hedge funds have recently made changes to their positions in ALGS. Golden State Wealth Management LLC grew its position in Aligos Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 5,348 shares of the company's stock worth $44,000 after buying an additional 2,674 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in Aligos Therapeutics by 43.1% during the first quarter. Adage Capital Partners GP L.L.C. now owns 465,000 shares of the company's stock worth $3,836,000 after buying an additional 140,000 shares in the last quarter. Heights Capital Management Inc. acquired a new stake in Aligos Therapeutics during the first quarter worth approximately $1,992,000. Readystate Asset Management LP acquired a new stake in Aligos Therapeutics during the first quarter worth approximately $375,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Aligos Therapeutics during the first quarter worth approximately $3,399,000. Institutional investors and hedge funds own 60.43% of the company's stock. Aligos Therapeutics Company Profile (Get Free Report)Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).Featured ArticlesFive stocks we like better than Aligos TherapeuticsStocks with Unusual Volume: How to Find Unusual Volume Stocks in Real TimeLogitech Eyes Breakout Before Earnings—Citigroup Sees 30% UpsideWhat is a Death Cross in Stocks?3 Regional Bank Stocks That Crushed Q3 EarningsDo ETFs Pay Dividends? What You Need to KnowFreeport-McMoRan Posts Strong Earnings Despite Indonesia ShutdownThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Aligos Therapeutics Right Now?Before you consider Aligos Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aligos Therapeutics wasn't on the list.While Aligos Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here